Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FATEBullishIndustry Newsnews

High materiality7/10

Fate's FT819 LN data shows 100% renal response, supports registrational path

Oct 26, 2026, 7:23 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong early-phase efficacy signals (100% renal response, ~50% proteinuria drop) plus a simpler conditioning approach and on-demand manufacturing could pique investor interest and shift near-term sentiment, despite early-stage data.

AI summary

What happened, with direct paths to the underlying reporting

Fate Therapeutics announced updated Phase 1 data for FT819 in lupus nephritis, reporting 100% renal response at six months and about a 50% reduction in proteinuria with less-intensive bendamustine conditioning. The results bolster the RECLAIM-LN program as a potential registrational path for FT819 in refractory SLE with LN and highlight a simple, on-demand, off-the-shelf CAR-T approach that could broaden access.

FT819 in active LN shows 100% renal response at Month 6.
Proteinuria reduced ~50% observed in the cohort.
Less-intensive bendamustine conditioning used for RECLAIM-LN.
No dose-limiting toxicities or high-grade CRS/ICANS observed.
On-demand, off-the-shelf CAR-T could enable community dosing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.